REVEAL study: long-term analysis of ruxolitinib in patients with polycythemia vera after hydroxyurea

REVEAL study: long-term analysis of ruxolitinib in patients with polycythemia vera after hydroxyurea

Long-term 5-year data continues to show RESPONSE to ruxolitinib in polycythemia veraПодробнее

Long-term 5-year data continues to show RESPONSE to ruxolitinib in polycythemia vera

Insights into the REVEAL trial: the efficacy of ruxolitinib for the treatment of patients with PVПодробнее

Insights into the REVEAL trial: the efficacy of ruxolitinib for the treatment of patients with PV

Understanding the Role of Ruxolitinib in Patients With Polycythemia VeraПодробнее

Understanding the Role of Ruxolitinib in Patients With Polycythemia Vera

Case 2: Ruxolitinib Treatment for Polycythemia VeraПодробнее

Case 2: Ruxolitinib Treatment for Polycythemia Vera

A RESPONSE to ruxolitinib: update on 4-year trial follow-upПодробнее

A RESPONSE to ruxolitinib: update on 4-year trial follow-up

Polycythemia Vera: Optimizing Ruxolitinib’s RoleПодробнее

Polycythemia Vera: Optimizing Ruxolitinib’s Role

Utilization of Ruxolitinib for Polycythemia VeraПодробнее

Utilization of Ruxolitinib for Polycythemia Vera

Ruxolitinib for Relapsed/Refractory or Hydroxyurea-Intolerant Polycythemia Vera PatientsПодробнее

Ruxolitinib for Relapsed/Refractory or Hydroxyurea-Intolerant Polycythemia Vera Patients

Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia veraПодробнее

Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera

Results from the MAJIC-PV trial: ruxolitinib vs BAT for hydroxyurea resistant/intolerant PVПодробнее

Results from the MAJIC-PV trial: ruxolitinib vs BAT for hydroxyurea resistant/intolerant PV

Ruxolitinib in combination with abemaciclib for patients with primary or post-PV/ET myelofibrosisПодробнее

Ruxolitinib in combination with abemaciclib for patients with primary or post-PV/ET myelofibrosis

Polycythemia Vera: Ruxolitinib Trial DataПодробнее

Polycythemia Vera: Ruxolitinib Trial Data

Role of Ruxolitinib in Polycythemia VeraПодробнее

Role of Ruxolitinib in Polycythemia Vera

Phase II Study of Ruxolitinib: Essential Thrombocythemia(ET) Refractory to/Intolerant of HydroxyureaПодробнее

Phase II Study of Ruxolitinib: Essential Thrombocythemia(ET) Refractory to/Intolerant of Hydroxyurea

Further Analysis of RESPONSE Trial Data Validates Ruxolitinib as Second-Line TherapyПодробнее

Further Analysis of RESPONSE Trial Data Validates Ruxolitinib as Second-Line Therapy

The Role of Ruxolitinib in Treating Polycythemia VeraПодробнее

The Role of Ruxolitinib in Treating Polycythemia Vera

An update on the safety and efficacy of rusfertide in polycythemia veraПодробнее

An update on the safety and efficacy of rusfertide in polycythemia vera

Hydroxyurea Intolerance/Resistance in Polycythemia veraПодробнее

Hydroxyurea Intolerance/Resistance in Polycythemia vera

События